458 related articles for article (PubMed ID: 15847207)
21. Diagnosis and management of common chronic metabolic complications in HIV-infected patients.
Bader MS; Kelly DV
Postgrad Med; 2008 Nov; 120(4):17-27. PubMed ID: 19020362
[TBL] [Abstract][Full Text] [Related]
22. [Increased cardiovascular risk in HIV patients].
Wierema TK
Ned Tijdschr Geneeskd; 2010; 154():A788. PubMed ID: 20456808
[TBL] [Abstract][Full Text] [Related]
23. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk.
Barbaro G
Am J Ther; 2006; 13(3):248-60. PubMed ID: 16772767
[TBL] [Abstract][Full Text] [Related]
24. [Interactions of cardiac and antiretroviral medication].
Egger S; Drewe J
Herz; 2005 Sep; 30(6):493-503. PubMed ID: 16170680
[TBL] [Abstract][Full Text] [Related]
25. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
Leonard EG; McComsey GA
Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
[TBL] [Abstract][Full Text] [Related]
26. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
[TBL] [Abstract][Full Text] [Related]
27. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score.
Mangili A; Gerrior J; Tang AM; O'Leary DH; Polak JK; Schaefer EJ; Gorbach SL; Wanke CA
Clin Infect Dis; 2006 Dec; 43(11):1482-9. PubMed ID: 17083026
[TBL] [Abstract][Full Text] [Related]
28. HAART to heart: highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults.
Lipshultz SE; Mas CM; Henkel JM; Franco VI; Fisher SD; Miller TL
Expert Rev Anti Infect Ther; 2012 Jun; 10(6):661-74. PubMed ID: 22734956
[TBL] [Abstract][Full Text] [Related]
29. Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk.
Barbaro G; Barbarini G
Chemotherapy; 2006; 52(4):161-5. PubMed ID: 16675900
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular disease and HIV infection: host, virus, or drugs?
Martínez E; Larrousse M; Gatell JM
Curr Opin Infect Dis; 2009 Feb; 22(1):28-34. PubMed ID: 19532078
[TBL] [Abstract][Full Text] [Related]
31. Clinical cardiac manifestations of HIV infection: a review of current literature.
Chu WW; Sosman JM; Stein JH
WMJ; 2002; 101(7):40-5, 39. PubMed ID: 12426919
[TBL] [Abstract][Full Text] [Related]
32. Insulin Resistance and the cardiometabolic syndrome in HIV infection.
Bevilacqua M; Dominguez LJ; Barbagallo M
J Cardiometab Syndr; 2009; 4(1):40-3. PubMed ID: 19245515
[TBL] [Abstract][Full Text] [Related]
33. Lipid abnormalities.
Dube M; Fenton M
Clin Infect Dis; 2003 Apr; 36(Suppl 2):S79-83. PubMed ID: 12652375
[TBL] [Abstract][Full Text] [Related]
34. N-terminal pro-B-type natriuretic peptide (NT-proBNP) in HIV-1 infected individuals on HAART.
Berg T; Zdunek D; Stalke J; Dupke S; Baumgarten A; Carganico A; Hess G
Eur J Med Res; 2007 Apr; 12(4):152-60. PubMed ID: 17509959
[TBL] [Abstract][Full Text] [Related]
35. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection.
Samaras K
J Antimicrob Chemother; 2008 Feb; 61(2):238-45. PubMed ID: 18070830
[TBL] [Abstract][Full Text] [Related]
36. Evaluating and managing cardiovascular disease risk factors in HIV-infected patients.
Top HIV Med; 2010 Dec; 18(5):164-8. PubMed ID: 21245517
[TBL] [Abstract][Full Text] [Related]
37. [HIV infection: emerging issues and new challenges].
Calza L; Manfredi R; Chiodo F
Recenti Prog Med; 2006 Dec; 97(12):771-80. PubMed ID: 17252736
[TBL] [Abstract][Full Text] [Related]
38. Endothelial function in HIV-infected patients with low or mild cardiovascular risk.
Blanco JJ; García IS; Cerezo JG; de Rivera JM; Anaya PM; Raya PG; García JG; López JR; Hernández FJ; Rodríguez JJ
J Antimicrob Chemother; 2006 Jul; 58(1):133-9. PubMed ID: 16702174
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
Kwong GP; Ghani AC; Rode RA; Bartley LM; Cowling BJ; da Silva B; Donnelly CA; van Sighem AI; Cameron DW; Danner SA; de Wolf F; Anderson RM
AIDS; 2006 Oct; 20(15):1941-50. PubMed ID: 16988515
[TBL] [Abstract][Full Text] [Related]
40. Endothelial and platelet function alterations in HIV-infected patients.
Gresele P; Falcinelli E; Sebastiano M; Baldelli F
Thromb Res; 2012 Mar; 129(3):301-8. PubMed ID: 22192157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
